RxDoctor Payments Data

Francisco Pons, MD

Nephrology · Miami, FLNPI 1508849027

Payments from drug & device makers

$5,801in general payments, 2019–2025

Across 347 payments — averaging $16.72 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Vifor Pharma, Inc.$2K
  • AstraZeneca$852
  • OPKO Pharmaceuticals, LLC$545
  • Amgen$407
  • Akebia Therapeutics Inc$284
  • Fresenius USA Marketing, Inc.$276
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,58996%
  • Education$2134%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$5,801 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida

Medicare billing

Part B allowed, 2024
$163,584
Medicare patients
205
Services billed
1,307

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol1,968$1,319,647
JynarqueTolvaptan50$983,479
JardianceEmpagliflozin813$578,269
VeltassaPatiromer Calcium Sorbitex383$373,709
VelphoroSucroferric Oxyhydroxide40$115,627
Sevelamer Carbonate730$77,462
DapagliflozinDapagliflozin Propanediol96$46,283
LokelmaSodium Zirconium Cyclosilicate54$39,970
RayaldeeCalcifediol24$39,232
XphozahTenapanor Hcl11$37,968
KerendiaFinerenone36$27,349
ProcritEpoetin Alfa29$22,076
Potassium Citrate ErPotassium Citrate248$18,474
Calcitriol1,156$10,537
Calcium Acetate165$9,251

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Lokelma$852$1,359,6162,022 claims
Otsuka America Pharmaceutical, Inc.Jynarque$228$983,47950 claims
Boehringer IngelheimJardiance$79$578,269813 claims
Fresenius USA Marketing, Inc.Velphoro$276$115,62740 claims
OPKO Pharmaceuticals, LLCRayaldee$545$39,23224 claims
BayerKerendia$189$27,34936 claims
NovartisEntresto$41$7,53511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 756 nephrology providers in Florida.

Other nephrology in Miami

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →